Neuroendocrine (HPA axis) and clinical correlates during fluvoxamine and amitriptyline treatment
- PMID: 15741004
- DOI: 10.1016/j.psychres.2003.12.030
Neuroendocrine (HPA axis) and clinical correlates during fluvoxamine and amitriptyline treatment
Abstract
The effect of amitriptyline on hypothalamic-pituitary-adrenocortical (HPA) axis activity was compared with that of fluvoxamine in 38 patients suffering from DMS-IV major depressive disorder. Basal plasma adrenocorticotropic hormone and cortisol levels were determined in the so-called "observation window" of an hour (08:00-09:00 h), and cortisol levels were determined again at 20:00 h. Clinical and biochemical assessments were performed before therapy (T0), at day 14 (T14), and at day 42 (T42) of the course of antidepressant treatment. At T0, neuroendocrine parameters did not differ in patients from those in controls, except for the ratio between cortisol levels at 20:00 h and the mean level of the "window" (ratio F20/F8), which was significantly higher, suggesting a dysregulation of the circadian pattern of cortisol. Although a decrease in the ratio F20/F8 was already apparent at T14 of both treatments, the repeated measures analysis of variance failed to demonstrate a significant variation with time (T0, T14, and T42) and with treatment (amitriptyline and fluvoxamine) for any hormonal measure. At T42, both treated groups showed a similar level of clinical improvement. Our results did not demonstrate any effect of antidepressant therapy on the cortisol circadian rhythm abnormality.
Similar articles
-
Evidence of basal pituitary-adrenal overactivity in first episode, drug naïve patients with schizophrenia.Psychoneuroendocrinology. 2004 Sep;29(8):1065-70. doi: 10.1016/j.psyneuen.2003.08.011. Psychoneuroendocrinology. 2004. PMID: 15219658 Clinical Trial.
-
Hypothalamic-pituitary-adrenal axis dysregulation among diabetic outpatients.Psychiatry Res. 1990 Jan;31(1):31-7. doi: 10.1016/0165-1781(90)90106-f. Psychiatry Res. 1990. PMID: 2156275
-
Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications.J Clin Endocrinol Metab. 2001 Aug;86(8):3787-94. doi: 10.1210/jcem.86.8.7778. J Clin Endocrinol Metab. 2001. PMID: 11502812
-
The hypothalamic-pituitary-adrenal axis in anorexia nervosa.Psychiatry Res. 1996 Apr 16;62(1):75-83. doi: 10.1016/0165-1781(96)02991-5. Psychiatry Res. 1996. PMID: 8739117 Review.
-
Implications of hypothalamic-pituitary-adrenal axis functioning in posttraumatic stress disorder.J Am Psychiatr Nurses Assoc. 2011 Nov-Dec;17(6):393-403. doi: 10.1177/1078390311420564. J Am Psychiatr Nurses Assoc. 2011. PMID: 22142976 Review.
Cited by
-
Does improving mood in depressed patients alter factors that may affect cardiovascular disease risk?J Psychiatr Res. 2009 Dec;43(16):1246-52. doi: 10.1016/j.jpsychires.2009.05.006. Epub 2009 Jul 4. J Psychiatr Res. 2009. PMID: 19577757 Free PMC article. Clinical Trial.
-
Salivary cortisol in women with major depressive disorder under selective serotonin reuptake inhibitors therapy.Arch Womens Ment Health. 2013 Apr;16(2):139-47. doi: 10.1007/s00737-013-0329-z. Epub 2013 Jan 31. Arch Womens Ment Health. 2013. PMID: 23371518 Free PMC article.
-
Cortisol as a Biomarker of Mental Disorder Severity.J Clin Med. 2021 Nov 8;10(21):5204. doi: 10.3390/jcm10215204. J Clin Med. 2021. PMID: 34768724 Free PMC article. Review.
-
Pituitary side effects of old and new drugs.J Endocrinol Invest. 2014 Oct;37(10):917-23. doi: 10.1007/s40618-014-0133-2. Epub 2014 Jul 29. J Endocrinol Invest. 2014. PMID: 25070042 Review.
-
Fluvoxamine versus other anti-depressive agents for depression.Cochrane Database Syst Rev. 2010 Mar 17;2010(3):CD006114. doi: 10.1002/14651858.CD006114.pub2. Cochrane Database Syst Rev. 2010. PMID: 20238342 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous